Physician profile
John C Steers
NPI 1013912708
$3,559.97
in general payments reported to CMS, 2019-2025
24 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $107 · 2021: $440 · 2022: $967 · 2023: $681 · 2024: $289 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $834.10 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $424.75 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $296.85 | 2019-2023 | |
| Heartflow, INC. | $289.39 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $282.56 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $254.75 | 2019-2022 | |
| Boston Scientific Corporation | $220.96 | 2021-2023 | Watchman Access System |
| Daiichi Sankyo INC. | $158.78 | 2023-2025 | Injectafer |
| Amarin Pharma, INC. | $150.92 | 2019-2020 | |
| Amgen INC. | $116.38 | 2019-2023 | Repatha |
| Abbott Laboratories | $69.58 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Scpharmaceuticals INC. | $67.92 | 2024-2025 | |
| Veryan Medical Incorporated | $58.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $49.30 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.45 | 2023-2025 | Lifevest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $44.11 | 2021 | |
| Portola Pharmaceuticals, LLC | $33.17 | 2019 | |
| Philips North America LLC | $32.69 | 2023 | |
| Kiniksa Pharmaceuticals, Ltd. | $30.17 | 2022-2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $28.20 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $20.81 | 2019 | |
| Altathera Pharmaceuticals LLC | $19.40 | 2024 | Sotalol Hydrochloride |
| Arbor Pharmaceuticals, INC. | $14.68 | 2019 | |
| Esperion Therapeutics, INC. | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Steers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.